FOXO4-DRI (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection daily, every day, for the length of the course. This is a continuous daily protocol rather than a pulsed one, and the only thing that changes across the cycle is the dose, which steps up every 4 weeks. At 10 mg/mL, 1 unit on a U-100 syringe delivers 100 mcg, so the entire dose range sits between 2.5 and 5 units and no dose comes close to needing a second injection. Because every administration is well under 10 units (0.10 mL), a 30 unit or 50 unit insulin syringe is far easier to read accurately than a full 100 unit barrel; the 375 mcg step reads as three and three quarter units, which is why a barrel with half unit graduations is worth having for weeks 5 to 8. The master sheet gives no required time of day, so consistency from day to day matters more than the clock. Sites are rotated systematically across abdomen, thighs, and upper arms, with successive injections placed at least 1 inch apart to reduce local irritation. The site is cleaned with an alcohol swab and allowed to dry, and the injection is given slowly and steadily without aspiration.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 4: 250 mcg daily, the entry dose, drawn as 2.5 units at 10 mg/mL.
• Weeks 5 to 8: the dose steps up to 375 mcg daily, drawn as 3.75 units. A course may be stopped here, since 8 weeks is the shortest planned length.
• Weeks 9 to 12: 500 mcg daily, drawn as 5 units, the top of the master sheet's range.
• Weeks 13 to 16: 500 mcg daily is held rather than raised further, completing the longest planned course at 16 weeks.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 250 mcg = 2.5 units, 375 mcg = 3.75 units, and 500 mcg = 5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or below in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C and use within 1 month when reconstituted with bacteriostatic water; avoid repeated freeze-thaw.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• If longer storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation.

Supplies Needed

Planning below is based on a daily protocol of 8 to 16 weeks with titration, which works out to 1.75 mg per week at 250 mcg daily, about 2.6 mg per week at 375 mcg daily, and 3.5 mg per week at 500 mcg daily.

Peptide Vials (FOXO4-DRI, 10 mg vial):

• Across the full titration an 8 week course consumes about 17.5 mg, a 12 week course about 31.5 mg, and a 16 week course about 45.5 mg; the master sheet plans about 3 vials at 8 weeks, about 4 at 12 weeks, and about 5 at 16 weeks, which allows for the reconstituted solution being discarded at the 1 month mark rather than carried forward.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, and at 2.5 to 5 units per draw a 30 unit barrel is the practical choice.
• Full cycle: 56 syringes across 8 weeks, 84 across 12 weeks, and 112 across 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL of bacteriostatic water at this concentration, so a single 10 mL bottle covers 10 vials, which is more than enough for even the 16 week course.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin, which is 14 per week.
• Full cycle: 112 swabs across 8 weeks (2 boxes of 100 count) and 224 across 16 weeks (3 boxes of 100 count).

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe, typically 29 to 31 gauge with a 0.5 inch needle, for every injection, and dispose of it in a sharps container.
• Rotate injection sites across abdomen, thighs, and upper arms, placing successive injections at least 1 inch apart to reduce local irritation.
• Clean the injection site with an alcohol swab and allow it to dry fully before injecting.
• Inject slowly and steadily; there is no need to aspirate for subcutaneous injections.
• Document the daily dose and the site used, since a 16 week daily course only holds together if the titration steps and the rotation pattern are tracked rather than remembered.
• Regulatory Note: FOXO4-DRI has no approved therapeutic indication in any jurisdiction and no human clinical safety or efficacy data currently exist, so tolerability in humans remains uncharacterized. For research use only; not for human consumption.

How This Works

FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4-p53 protein interaction. In normal cells, FOXO4 binds to p53 and sequesters it in the nucleus. In senescent cells, disrupting that interaction causes p53 to translocate to the mitochondria, triggering apoptotic cell death specifically in aged, dysfunctional cells while sparing healthy ones. Animal studies have demonstrated that FOXO4-DRI can reduce senescent cell burden, improve tissue function, and mitigate age-related pathologies. The peptide's D-retro-inverso configuration enhances its stability and its resistance to proteolytic degradation.

Benefits & Side Effects

Observations from the published record.

• Promotes selective clearance of senescent cells in various tissues, including aged organs and pathological conditions.
• Animal studies show improvements in tissue regeneration, reduced inflammation, and enhanced organ function following senescent cell clearance.
• In aged mice, FOXO4-DRI treatment improved testosterone levels and markers of cellular health.
• Preclinical work extends beyond aging models: the peptide has induced apoptosis in keloid senescent fibroblasts and has ameliorated bleomycin-induced pulmonary fibrosis in mice.
• No human clinical safety or efficacy data currently exist, so tolerability in humans remains uncharacterized.
• Injection-site reactions such as mild redness and irritation may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced, nutrient-dense diet rich in antioxidants and anti-inflammatory compounds.
• Combine regular resistance training and cardiovascular activity to support cellular health and metabolic function.
• Prioritize sleep quality and stress management, both of which influence cellular senescence pathways.
• Stay well-hydrated and avoid excessive alcohol consumption or smoking, both of which can accelerate cellular aging.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis (Nature Cell): original FOXO4-DRI discovery.
2. FOXO4-DRI induces keloid senescent fibroblast apoptosis (Nature Communications Biology).
3. FOXO4-DRI alleviates age-related testosterone secretion insufficiency (Aging, Albany NY).
4. FOXO4 peptide ameliorates bleomycin-induced pulmonary fibrosis in mice (J Cellular and Molecular Medicine).